相关实验视频
Updated: Sep 17, 2025

05:57
Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
13.3K
混合性禁止因:D- (RLARLAR) 2 增强稳定性和对肥胖的活体影响
Lai Yue Chan1, Benjamin D Weger2, Meltem Weger2
1Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072, Australia.
Journal of the American Chemical Society
|July 1, 2025
概括
新的禁忌针对白色脂肪组织,以减少体重和脂肪细胞的扩张. 这种肥胖治疗方法诱导线粒体脱,
科学领域:
- 生物化学
- 代谢科学
- 药理学
背景情况:
- 肥胖是一个全球流行病,也是2型糖尿病的主要风险因素.
- 药物疗法提供了一种补充方式来改变持续减肥的生活方式.
研究的目的:
- 设计和设计新一代基于的治疗药物, 针对白脂肪组织.
- 评估这些新型在减轻体重和脂肪细胞扩张方面的有效性.
主要方法:
- 开发基于的治疗方法.
- 在高脂肪饮食诱导的肥胖小鼠模型中给予.
- 对体重减轻和脂肪细胞功能的评估.
主要成果:
- 在肥胖小鼠模型中,工程禁止显著降低了体重.
- 化合物PTP-r (用d-arginine替代的禁止素-TP01) 显示出强大的疗效.
- 在脂肪组织中诱导线粒体脱.
结论:
- 下一代针对脂肪的禁蛋白对治疗肥胖有前途.
- 这些可以有效地抑制脂肪细胞的扩张和体重.
- 良好的临床前安全性资料表明,它有可能用于治疗肥胖和代谢综合征.
相关概念视频
Chirality in Nature
13.9K
Chirality is the most intriguing yet essential facet of nature, governing life’s biochemical processes and precision. It can be observed from a snail shell pattern in a macroscopic world to an amino acid, the minutest building block of life. Most of the snails around the world have right-coiled shells because of the intrinsic chirality in their genes. All the amino acids present in the human body exist in an enantiomerically pure state, except for glycine - the sole achiral amino acid.
13.9K
Prochirality
4.0K
The concept of prochirality leads to the nomenclature of the individual faces of a molecule and plays a crucial role in the enantioselective reaction. It is a concept where two or more achiral molecules react to produce chiral products. A typical process is the reaction of an achiral ketone to generate a chiral alcohol. Here, the achiral reactant reacts with an achiral reducing agent, sodium borohydride, to generate an equimolar mixture of the chiral enantiomers of the product. For example, an...
4.0K
Glucagon-like Receptor Agonists
433
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
433

